Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verinurad and Febuxostat in Albuminuric T2DM
NCT03118739Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperuricemia and chronic kidney disease (CKD) comparing Verinurad + Febuxostat with Placebo (2 arms). Primary endpoint: Urinary Albumin to Creatinine Ratio at 12 weeks. Started May 2017; status: completed.
02
Drugs
verinurad
03
Conditions
hyperuricemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03118739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118739.